Wellington Management Group LLP Has $314.85 Million Holdings in Dianthus Therapeutics, Inc. $DNTH

Wellington Management Group LLP grew its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 24.4% in the 2nd quarter, Holdings Channel reports. The fund owned 3,229,882 shares of the company’s stock after purchasing an additional 634,099 shares during the quarter. Wellington Management Group LLP owned about 0.06% of Dianthus Therapeutics worth $314,849,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its stake in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the last quarter. UBS Group AG grew its position in Dianthus Therapeutics by 342.6% in the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after purchasing an additional 469,547 shares during the last quarter. BNP Paribas Financial Markets grew its position in Dianthus Therapeutics by 1,275.3% in the 4th quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock worth $19,606,000 after purchasing an additional 441,156 shares during the last quarter. SummitTX Capital L.P. increased its holdings in shares of Dianthus Therapeutics by 13.8% during the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after purchasing an additional 12,118 shares during the period. Finally, California State Teachers Retirement System increased its holdings in shares of Dianthus Therapeutics by 155.5% during the 1st quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock worth $3,406,000 after purchasing an additional 24,697 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Insider Activity at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer owned 65,292 shares of the company’s stock, valued at approximately $7,058,718.12. This represents a 71.77% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 260,554 shares of company stock worth $27,211,775. Insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Price Performance

DNTH stock opened at $105.84 on Monday. The company has a market cap of $5.79 billion, a P/E ratio of -25.50 and a beta of 1.22. Dianthus Therapeutics, Inc. has a twelve month low of $22.81 and a twelve month high of $117.88. The business has a fifty day moving average of $103.59 and a 200-day moving average of $87.32.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. HC Wainwright lifted their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Wedbush raised their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.